Inquire Before Buying - Transthyretin Amyloidosis Treatment Market Report by 2032

Global Transthyretin Amyloidosis Treatment Market Research Report: Forecast (2026-2032)

Transthyretin Amyloidosis Treatment Market - By Type (ATTR amyloidosis with polyneuropathy, ATTR amyloidosis with cardiomyopathy), By Disease Type (Hereditary Transthyretin Amyloid......osis, Polyneuropathy, Cardiomyopathy, Mixed type, Wild-type transthyretin amyloidosis), By Drug Type (Tafamidis, Patisiran, Inotersen, Other drug types), By Route of Administration (Oral, Parental), By Distribution Channel (Hospital pharmacy, Retail drug stores, Online pharmacy), and others Read more

Healthcare
Nov 2025
Pages 163
Report Format: PDF, Excel, PPT

Global Transthyretin Amyloidosis Treatment Market Size: Forecast (2026-2032)

The Global Transthyretin Amyloidosis Treatment Market size is valued at around USD5.88 billion in 2025 and is projected to reach USD13.58 billion by 2032. Along with this, the market is estimated to grow at a CAGR of around 12.70% during the forecast period, i.e., 2026-32.

Global Transthyretin Amyloidosis Treatment Market Outlook:

The Global Transthyretin (TTR) Amyloidosis Treatment Market landscape is expanding steadily as disease awareness, diagnostic capacity, and access to RNA-based and stabilizer therapies improve worldwide. For instance, ATTR-CM prevalence continues to dominate the region, like the United States, estimated approximately 120,000 people may have ATTR-CM, though most remain undiagnosed.

Moreover, recent commercial launches are reshaping treatment access. For instance, Ionis Pharmaceuticals’ eplontersen, co-commercialized with AstraZeneca, received U.S. FDA approval in 2024 for ATTR polyneuropathy, strengthening competition against Pfizer’s tafamidis, which generated USD3.3 billion in 2023 global sales.

Furthermore, growing retail distribution networks are also supporting therapy accessibility. For instance, the U.S. National Association of Chain Drug Stores (NACDS) reports over 40,000 retail drug stores nationally in 2024, improving specialty-drug dispensing penetration. Similarly, online pharmacy adoption continues to rise, with the FDA noting accelerated enrollment in regulated digital pharmacies, driven by chronic-disease prescription demand and home-delivery trends.

Overall, rising diagnostic infrastructure combined with new RNA, antisense, and stabilizer therapies is expected to keep expanding global treatment uptake and geographic reach.

Global Transthyretin Amyloidosis Treatment Market Recent Developments:

June 2025: The European Commission approved vutrisiran (AMVUTTRA) for patients with either wild-type or hereditary ATTR cardiomyopathy. This approval means the treatment can now be prescribed across all EU countries. It expands access to an RNA-based therapy that lowers transthyretin levels and helps slow heart damage in ATTR-CM patients. The decision was based on strong clinical results from the HELIOS-B study.
February 2024: The FDA granted Fast Track designation to eplontersen, developed by Ionis and AstraZeneca, for treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM). This designation helps speed up the review and development process because ATTR-CM is a serious, progressive condition with limited treatment options. Fast Track status allows closer FDA guidance and faster access to new clinical data, supporting quicker progress toward approval.

Global Transthyretin Amyloidosis Treatment Market Scope:

Category	Segments
By Type	ATTR amyloidosis with polyneuropathy, ATTR amyloidosis with cardiomyopathy),
By Disease Type	Hereditary Transthyretin Amyloidosis, Polyneuropathy, Cardiomyopathy, Mixed type, Wild-type transthyretin amyloidosis),
By Drug Type	Tafamidis, Patisiran, Inotersen, Other drug types),
By Route of Administration	Oral, Parental),
By Distribution Channel	Hospital pharmacy, Retail drug stores, Online pharmacy), and others

Global Transthyretin Amyloidosis Treatment Market Drivers:

Increasing Investments for Rare-Disease Research and Clinical Infrastructure

Growing investment in rare-disease research and clinical infrastructure is accelerating progress in transthyretin amyloidosis (ATTR) treatment worldwide. The U.S. National Institutes of Health (NIH) remains the largest public funder of rare-disease research, investing about USD26 million for rare disease conditions, including amyloidosis.

Additionally, governments across Europe and Asia have also expanded rare-disease infrastructure. In September 2024, the European Commission announced that the ERDERA Partnership will mobilize a total of USD 410.4 million to support rare-disease research, covering prevention, diagnosis, and treatment efforts, supporting biomarker discovery, advanced imaging, and precision-medicine tools across EU tertiary hospitals.

Moreover, Asia is investing as well. Japan’s AMED allocated more than USD125 million in 2024 to diseases, including rare-disease genomics and protein-misfolding research, strengthening amyloidosis-related discovery programs. Meanwhile, the Canadian Institutes of Health Research (CIHR) committed USD22.75 million to rare-disease diagnostics and precision-therapy research in 2023–24.

Market Segmentation
Introduction
1. Product Definition
2. Research Process
3. Assumptions
Executive Summary
Global Transthyretin Amyloidosis Treatment Market Policies, Regulations, Product Standards
Global Transthyretin Amyloidosis Treatment Market Trends & Development
Global Transthyretin Amyloidosis Treatment Market Dynamics
1. Growth Drivers
2. Challenges
3. Trends
4. Opportunities
Global Transthyretin Amyloidosis Treatment Market Hotspot & Opportunities
Global Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
1. Market Size & Analysis
  1. By Revenue (USD Million)
2. Market Share & Analysis
  1. By Type- (USD Million)
    1. ATTR amyloidosis with polyneuropathy
    2. ATTR amyloidosis with cardiomyopathy
  2. By Disease Type- (USD Million)
    1. Hereditary Transthyretin Amyloidosis
      1. Polyneuropathy
      2. Cardiomyopathy
      3. Mixed type
    2. Wild-type transthyretin amyloidosis
  3. By Drug Type- (USD Million)
    1. Tafamidis
    2. Patisiran
    3. Inotersen
    4. Other drug types
  4. By Route of Administration
    1. Oral
    2. Parental
  5. By Distribution Channel
    1. Hospital pharmacy
    2. Retail drug stores
    3. Online pharmacy
  6. By Region
    1. North America
    2. South America
    3. Europe
    4. Middle East & Africa
    5. Asia-Pacific
  7. By Company
    1. Competition Characteristics
    2. Market Share & Analysis
North America Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
1. Market Size & Analysis
  1. By Revenue (USD Million)
2. Market Share & Analysis
  1. By Type- (USD Million)
  2. By Disease Type- (USD Million)
  3. By Route of Administration - (USD Million)
  4. By Drug Type - (USD Million)
  5. By Distribution Channel - (USD Million)
  6. By Country
    1. The US
    2. Canada
    3. Mexico
3. The US Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenue (USD Million)
  2. Market Share & Analysis
    1. By Type- (USD Million)
    2. By Disease Type- (USD Million)
    3. By Route of Administration - (USD Million)
    4. By Drug Type - (USD Million)
    5. By Distribution Channel - (USD Million)
4. Canada Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenue (USD Million)
  2. Market Share & Analysis
    1. By Type- (USD Million)
    2. By Disease Type- (USD Million)
    3. By Route of Administration - (USD Million)
    4. By Drug Type - (USD Million)
    5. By Distribution Channel - (USD Million)
5. Mexico Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenue (USD Million)
  2. Market Share & Analysis
    1. By Type- (USD Million)
    2. By Disease Type- (USD Million)
    3. By Route of Administration - (USD Million)
    4. By Drug Type - (USD Million)
    5. By Distribution Channel - (USD Million)
South America Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
1. Market Size & Analysis
  1. By Revenue (USD Million)
2. Market Share & Analysis
  1. By Type- (USD Million)
  2. By Disease Type- (USD Million)
  3. By Route of Administration - (USD Million)
  4. By Drug Type - (USD Million)
  5. By Distribution Channel - (USD Million)
  6. By Country
    1. Brazil
    2. Argentina
    3. Rest of South America
3. Brazil Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenue (USD Million)
  2. Market Share & Analysis
    1. By Type- (USD Million)
    2. By Disease Type- (USD Million)
    3. By Route of Administration - (USD Million)
    4. By Drug Type - (USD Million)
    5. By Distribution Channel - (USD Million)
4. Argentina Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenue (USD Million)
  2. Market Share & Analysis
    1. By Type- (USD Million)
    2. By Disease Type- (USD Million)
    3. By Route of Administration - (USD Million)
    4. By Drug Type - (USD Million)
    5. By Distribution Channel - (USD Million)
Europe Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
1. Market Size & Analysis
  1. By Revenue (USD Million)
2. Market Share & Analysis
  1. By Type- (USD Million)
  2. By Disease Type- (USD Million)
  3. By Route of Administration - (USD Million)
  4. By Drug Type - (USD Million)
  5. By Distribution Channel - (USD Million)
  6. By Country
    1. The UK
    2. Italy
    3. Germany
    4. France
    5. Spain
    6. Rest of Europe
3. The US Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenue (USD Million)
  2. Market Share & Analysis
    1. By Type- (USD Million)
    2. By Disease Type- (USD Million)
    3. By Route of Administration - (USD Million)
    4. By Drug Type - (USD Million)
    5. By Distribution Channel - (USD Million)
4. Italy Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenue (USD Million)
  2. Market Share & Analysis
    1. By Type- (USD Million)
    2. By Disease Type- (USD Million)
    3. By Route of Administration - (USD Million)
    4. By Drug Type - (USD Million)
    5. By Distribution Channel - (USD Million)
5. Germany Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenue (USD Million)
  2. Market Share & Analysis
    1. By Type- (USD Million)
    2. By Disease Type- (USD Million)
    3. By Route of Administration - (USD Million)
    4. By Drug Type - (USD Million)
    5. By Distribution Channel - (USD Million)
6. France Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenue (USD Million)
  2. Market Share & Analysis
    1. By Type- (USD Million)
    2. By Disease Type- (USD Million)
    3. By Route of Administration - (USD Million)
    4. By Drug Type - (USD Million)
    5. By Distribution Channel - (USD Million)
7. Spain Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenue (USD Million)
  2. Market Share & Analysis
    1. By Type- (USD Million)
    2. By Disease Type- (USD Million)
    3. By Route of Administration - (USD Million)
    4. By Drug Type - (USD Million)
    5. By Distribution Channel - (USD Million)
Middle East & Africa Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
1. Market Size & Analysis
  1. By Revenue (USD Million)
2. Market Share & Analysis
  1. By Type- (USD Million)
  2. By Disease Type- (USD Million)
  3. By Route of Administration - (USD Million)
  4. By Drug Type - (USD Million)
  5. By Distribution Channel - (USD Million)
  6. By Country
    1. Saudi Arabia
    2. UAE
    3. South Africa
    4. Rest of Middle East & Africa
3. Saudi Arabia Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenue (USD Million)
  2. Market Share & Analysis
    1. By Type- (USD Million)
    2. By Disease Type- (USD Million)
    3. By Route of Administration - (USD Million)
    4. By Drug Type - (USD Million)
    5. By Distribution Channel - (USD Million)
4. UAE Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenue (USD Million)
  2. Market Share & Analysis
    1. By Type- (USD Million)
    2. By Disease Type- (USD Million)
    3. By Route of Administration - (USD Million)
    4. By Drug Type - (USD Million)
    5. By Distribution Channel - (USD Million)
5. South Africa Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenue (USD Million)
  2. Market Share & Analysis
    1. By Type- (USD Million)
    2. By Disease Type- (USD Million)
    3. By Route of Administration - (USD Million)
    4. By Drug Type - (USD Million)
    5. By Distribution Channel - (USD Million)
Asia-Pacific Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
1. Market Size & Analysis
  1. By Revenue (USD Million)
2. Market Share & Analysis
  1. By Type- (USD Million)
  2. By Disease Type- (USD Million)
  3. By Route of Administration - (USD Million)
  4. By Drug Type - (USD Million)
  5. By Distribution Channel - (USD Million)
  6. By Country
    1. China
    2. Japan
    3. India
    4. South Korea
    5. Australia
3. China Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenue (USD Million)
  2. Market Share & Analysis
    1. By Type- (USD Million)
    2. By Disease Type- (USD Million)
    3. By Route of Administration - (USD Million)
    4. By Drug Type - (USD Million)
    5. By Distribution Channel - (USD Million)
4. Japan Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenue (USD Million)
  2. Market Share & Analysis
    1. By Type- (USD Million)
    2. By Disease Type- (USD Million)
    3. By Route of Administration - (USD Million)
    4. By Drug Type - (USD Million)
    5. By Distribution Channel - (USD Million)
5. India Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenue (USD Million)
  2. Market Share & Analysis
    1. By Type- (USD Million)
    2. By Disease Type- (USD Million)
    3. By Route of Administration - (USD Million)
    4. By Drug Type - (USD Million)
    5. By Distribution Channel - (USD Million)
6. South Korea Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenue (USD Million)
  2. Market Share & Analysis
    1. By Type- (USD Million)
    2. By Disease Type- (USD Million)
    3. By Route of Administration - (USD Million)
    4. By Drug Type - (USD Million)
    5. By Distribution Channel - (USD Million)
7. Australia Transthyretin Amyloidosis Treatment Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenue (USD Million)
  2. Market Share & Analysis
    1. By Type- (USD Million)
    2. By Disease Type- (USD Million)
    3. By Route of Administration - (USD Million)
    4. By Drug Type - (USD Million)
    5. By Distribution Channel - (USD Million)
Global Transthyretin Amyloidosis Treatment Market Key Strategic Imperatives for Success & Growth
Competition Outlook
1. Company Profiles
  1. Acrotech Biopharma, LLC
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  2. Alnylam Pharmaceuticals Inc.
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  3. AstraZeneca Plc
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  4. Astellas Pharma Inc
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  5. Bridge-Myers Squibb Company
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  6. Ionis Pharmaceuticals, Inc
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  7. Johnson and Johnson
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  8. Prothena Bioscience Limited
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  9. Pfizer Inc.
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  10. SOM Innovation Biotech, SL
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  11. Others
Disclaimer

MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

FILL THE FORM TO INQUIRE BEFORE BUYING THIS REPORT

Name *

Email ID *

Country *

Contact Number *

Your Enquiry Details

Your data is 100% confidential & secure

By submitting, you agree to our Terms and Privacy Policy .

Flexible Licensing Options

We offer flexible licensing options to cater to varying organizational needs. Choose the pricing pack that best suits your requirements:

Buy Now

Related Reports

Talk to our Consultant

Customization Offered

Request Customization